Related Experiment Video
Updated: Jun 7, 2026

17:14
Compact Quantum Dots for Single-molecule Imaging
Published on: October 9, 2012
Quantum dot loaded immunomicelles for tumor imaging
Aristarchos Papagiannaros1, Jaydev Upponi, William Hartner
1Department of Pharmaceutical Sciences and Center for Pharmaceutical Biotechnology and Nanomedicine, 312 Mugar Life Sciences Building, Northeastern University, Boston, MA 02115, USA.
BMC Medical Imaging
|October 20, 2010
Summary
This study presents a novel tumor-targeted near-infrared imaging agent using antibody-coupled quantum dots. The targeted agent achieves ultrabright tumor imaging, doubling fluorescence intensity for enhanced early detection of metastases.
Area of Science:
- Biomedical Imaging
- Nanotechnology
- Oncology
Background:
- Optical imaging offers a rapid, minimally invasive method for animal tumor detection.
- Previous work developed a lipid-coated quantum dot system with enhanced fluorescence.
- A novel tumor-targeted near-infrared imaging agent was developed using antibody-coupled quantum dots.
Purpose of the Study:
- To develop and evaluate a novel tumor-targeted near-infrared imaging agent.
- To assess the agent's fluorescence intensity and imaging capabilities in animal models.
- To determine the potential for enhanced early detection of metastases.
Main Methods:
- Quantum dot (QD)-containing polymeric micelles were prepared from polyethylene glycol/phosphatidylethanolamine (PEG-PE) conjugates.
- Cancer-specific monoclonal antibody 2C5 was coupled to QD-loaded PEG-PE micelles.
- Animal models with 4T1 breast tumors and B16F10 melanoma lung metastases were used for imaging studies.
Main Results:
- The targeted agent produced ultrabright tumor images with double the fluorescence intensity compared to non-targeted micelles.
- High contrast images were achieved rapidly, visualizing tumors effectively.
- Ex vivo imaging detected melanoma nodes in a lung pseudometastatic model after a 24-hour washout period.
Conclusions:
- The targeted agent significantly enhances tumor visualization through ultrabright fluorescence.
- This development holds potential for improving the early detection of cancer metastases.
- The agent demonstrates rapid imaging and high contrast at a low dose.

